HFA Premium Access

Differences in VWF activity in patients with von Willebrand disease type 2A versus LVAD patients with the acquired von Willebrand syndrome.

Presentation

About the speaker

Doctor Marc Vanderheyden

Cardiovascular Research Center Aalst, Aalst (Belgium)
0 follower

67 more presentations in this session

Combined therapy with ACEI/ARB, beta-blocker, statin, antithrombotic drug and cardiovascular mortality in comorbide patients with heart failure, coronary artery disease, arterial hypertension

Thumbnail

Heart failure over 19 years: are we on the right way?

Thumbnail

B-blockers and prognosis in cardiac amyloidosis

Speaker: Doctor E. Repasos (Athens, GR)

Thumbnail

Safety and efficacy of valsartan-sacubitril in a cohort of patients with symptomatic heart failure receiving small doses of ACE

Speaker: Doctor A. Ntalianis (Athens, GR)

Thumbnail

Barriers and motivations to physical activity in heart failure patients; is a specific approach needed for women?

Speaker: Professor T. Jaarsma (Linkoping, SE)

Thumbnail

Access the full session

Poster Session 1 - Chronic Heart Failure – Treatment

Speakers: Doctor M. Vanderheyden, Doctor E. Repasos, Doctor A. Ntalianis, Professor T. Jaarsma
Thumbnail

About the event

Image

Heart Failure 2018 & World Congress on Acute Heart Failure

26 May - 29 May 2018

Sessions Presentations

This platform is supported by

logo Novo Nordisk